Addition of docetaxel to hormone therapy improves survival in

2014 ASCO Annual Meeting

Addition of docetaxel to hormone therapy improves survival in metastatic, hormone-sensitive prostate cancer

Listen now

Description

Prof Sweeney talks to ecancertv at ASCO 2014 about the findings from a federally funded phase III study, E3805, which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.

More Episodes

See all »

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

Published 07/15/14

2014 ASCO Annual Meeting

Published 07/15/14

ASCO 2014 roundup

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Published 07/11/14